Notes

1. Center for Behavioral Health Statistics and Quality, Results from the 2014 National Survey on Drug Use and Health: Detailed Tables (Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015), http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf; Aaron D. Fox et al., “Release from Incarceration, Relapse to Opioid Use and the Potential for Buprenorphine Maintenance Treatment: A Qualitative Study of the Perceptions of Former Inmates with Opioid Use Disorder,”Addiction Science & Clinical Practice 10, no. 2 (2015): 1–9; B. P. Smyth, J. Barry, E. Keenan, and K. Ducray, “Lapse and Relapse following Inpatient Treatment of Opiate Dependence,” Irish Medical Journal 103, no. 6 (2010): 176–79; and National Institute on Drug Abuse, “America’s Addiction to Opioids: Heroin and Prescription Drug Abuse,” a presentation by Nora D. Volkow, M.D., to the U.S. Senate Caucus on International Narcotics Control, May 14, 2014, https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2014/americas-addiction-to-opioids-heroin-prescription-drug-abuse.

2. Arthur Yin Fan et al., “Acupuncture’s Role in Solving the Opioid Epidemic: Evidence, Cost-Effectiveness, and Care Availability for Acupuncture as a Primary, Non-pharmacologic Method for Pain Relief and Management,” Journal of Integrative Medicine 15, no. 6 (2017): 411–25.

3. Xueqi Wang et al., “Electroacupuncture Suppresses Morphine Reward-Seeking Behavior: Lateral Hypothalamic Orexin Neurons Implicated,” Neuroscience Letter 661 (November 2017): 84–89.

4. Kenneth D. Kochanek et al., “Mortality in the United States, 2016,” National Center for Health Statistics Data Brief no. 293 (December 2017).

5. Substance Abuse and Mental Health Services Administration,Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health, HHS publication no. SMA17-5044,NSDUH seriesH-52(Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2017). https://www.samhsa.gov/data/.

6. Blue Cross Blue Shield website, https://www.bcbs.com, accessed June 2017.

7. Josh Katz, “Drug Deaths in America Are Rising Faster Than Ever,” New York Times, June 5, 2017, https://www.nytimes.com/interactive/2017/06/05/upshot/opioid-epidemic-drug-overdose-deaths-are-rising-faster-than-ever.html, accessed June 2017.

8. Christopher Moraff, “Feds’ Pill Crackdown Drives Pain Patients to Heroin,” Daily Beast, April 15, 2016, https://www.thedailybeast.com/feds-pill-crackdown-drives-pain-patients-to-heroin, accessed June 2017.

9. Surgeon General, U.S. Department of Health and Human Services, “Surgeon General’s Advisory on Nalaxone and Opioid Drugs,” April 5, 2018, https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html.

10. Jaymin Upadhyay et al., “Alterations in Brain Structure and Functional Connectivity in Prescription Opioid-Dependent Patients,”Brain 133, no. 7 (2010): 2098–114; and Howard S. Smith, “Opioid Metabolism,”Mayo Clinic Proceedings84, no. 7 (2009): 613–24.

11. Upadhyay et al., “Alterations in Brain Structure.”

12. Brown University, “Morphine Makes Lasting — and Surprising — Change in the Brain,”ScienceDaily, April 26, 2007, https://www.sciencedaily.com/releases/2007/04/070425142116.htm.

13. Thomas R. Kosten and Tony P. George, “The Neurobiology of Opioid Dependence: Implications for Treatment,”Science & Practice Perspectives1, no. 1 (2002): 13–20.

14. Alvaro Pascual-Leone et al., “The Plastic Human Brain Cortex,”Annual Review of Neuroscience28 (2005): 377–401.

15. Jennifer C. Tomaszczyk et al., “Negative Neuroplasticity in Chronic Traumatic Brain Injury and Implications for Neurorehabilitation,” Neuropsychology Review 24, no. 4 (2014): 409–27.

16. G. G. Xing et al., “Long-Term Synaptic Plasticity in the Spinal Dorsal Horn and Its Modulation by Electroacupuncture in Rats with Neuropathic Pain,” Experimental Neurology 208, no. 2 (2007): 323–32; Vitaly Napadow et al., “Somatosensory Cortical Plasticity in Carpal Tunnel Syndrome — A Cross-Sectional Fmri Evaluation,” NeuroImage 31, no. 2 (2006): 520–30; Vitaly Napadow et al., “Somatosensory Cortical Plasticity in Carpal Tunnel Syndrome Treated by Acupuncture,” Human Brain Mapping 28, no. 3 (2007): 159–71; and Chun-Zhi Liu, Jian Kong, and KeLun Wang, “Acupuncture Therapies and Neuroplasticity,” Neural Plasticity 2017 (April 27, 2017): Article ID 6178505.

17. Michael T. Treadway and Sara W. Lazar, “Meditation and Neuroplasticity: Using Mindfulness to Change the Brain,” chapter 7 in Assessing Mindfulness and Acceptance Processes in Clients, ed. Ruth A. Baer (Oakland, CA: New Harbinger, 2010); and Richard J. Davidson and Antoine Lutz, “Buddha’s Brain: Neuroplasticity and Meditation,” IEEE Signal Processing Magazine 25, no. 1 (2008): 171–74.

18. AnGee Baldini, Michael Von Korff, and Elizabeth H. B. Lin, “A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner’s Guide,” Primary Care Companion to CNS Disorders 14, no. 3 (2012): PCC.11m01326; and National Institute on Drug Abuse, “Health Consequences of Drug Misuse,” March 23, 2017, https://www.drugabuse.gov/related-topics/health-consequences-drug-misuse.

19. Jie Shi et al., “Traditional Chinese Medicine in Treatment of Opiate Addiction,” Acta Pharmacologica Sinica 27, no. 10 (2006): 1303–8.

20. R. A. Deyo, M. Von Korff, and D. Duhrkoop, “Opioids for Low Back Pain,” BMJ 350 (2015): g6380. doi:10.1136/bmj.g6380.

21. Icro Maremmani et al., “Subtyping Patients with Heroin Addiction at Treatment Entry: Factor Derived from the Self-Report Symptom Inventory (SCL-90),” Annals of General Psychiatry 9 (2010): 15.

22. Yuan Yu Chan et al., “The Benefit of Combined Acupuncture and Antidepressant Medication for Depression: A Systematic Review and Meta-analysis,” Journal of Affective Disorders 176 (May 1, 2015): 106–17; and “Mandated Benefit Review of H.B. 3972: An Act Relative to the Practice of Acupuncture,” Center for Health Information and Analysis, April 2015, http://www.aomsm.org/Resources/Documents/Research/BenefitReview-H3972-Acupuncture.pdf.

23. “New and Revised Standards Related to Pain Assessment and Management,” Joint Commission Perspectives 37, no. 7 (July 2017): 3–4, https://www.jointcommission.org/assets/1/18/Joint_Commission_Enhances_Pain_Assessment_and_Management _Requirements_for_Accredited_Hospitals1.PDF.

24. K. Beltaief et al., “Acupuncture versus Titrated Morphine in Acute Renal Colic: A Randomized Controlled Trial,”Journal of Pain Research11 (2018): 335–41. doi:10.2147 /JPR.S136299.

25. Dario Tedesco et al., “Drug-Free Interventions to Reduce Pain or Opioid Consumption after Total Knee Arthroplasty: A Systematic Review and Meta-analysis,” JAMA Surgery 152, no. 10 (2017): e172872; Shun Huang et al., “Effects of Transcutaneous Electrical Acupoint Stimulation at Different Frequencies on Perioperative Anesthetic Dosage, Recovery, Complications, and Prognosis in Video-Assisted Thoracic Surgical Lobectomy: A Randomized, Double-Blinded, Placebo-Controlled Trial,” Journal of Anesthesia. 31, no. 1 (2017): 58–65; Sven Asmussen et al., “Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care,” Journal of Intensive Care Medicine (2017); Li-Xin An et al., “Electro-Acupuncture Decreases Postoperative Pain and Improves Recovery in Patients Undergoing a Supratentorial Craniotomy,” American Journal of Chinese Medicine 42, no. 5 (2014): 1099–1109; and Sven Asmussen et al., “Effects of Acupuncture in Anesthesia for Craniotomy: A Meta-Analysis,” Journal of Neurosurgical Anesthesiology 29, no. 3 (2017): 219–27.

26. Juang-Geng Lin et al., “The Effect of High and Low Frequency Electroacupuncture in Pain after Lower Abdominal Surgery,” Pain 99, no. 3 (2002): 509–14; and Baoguo Wang et al., “Effect of the Intensity of Transcutaneous Acupoint Electrical Stimulation on the Postoperative Analgesic Requirement,” Anesthesia and Analgesia 85, no. 2 (1997): 406–13.

27. U.S. Centers for Disease Control and Prevention, National Center for Health Statistics, FastStats, “Ambulatory Care Use and Physician Office Visits,” https://www.cdc.gov/nchs/fastats/physician-visits.htm, accessed March 31, 2018.

28. R. Chou et al., “Nonpharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline,” Annals of Internal Medicine 166, no. 7 (2017): 493–505; and Amir Qaseem et al., “Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline from the American College of Physicians,” Annals of Internal Medicine 166, no. 7 (2017): 514–30.

29. Paul Crawford, Donald B. Penzien, and Remy Coeytaux, “Reduction in Pain Medication Prescriptions and Self-Reported Outcomes Associated with Acupuncture in a Military Patient Population,” Medical Acupuncture 29, no. 4 (2017): 229–31.

30. Benjamin Kligler, “Integrative Health in the Veterans Health Administration,” Medical Acupuncture 29, no. 4 (August 2017): 187–88; and Joseph M. Helms, “Medical Acupuncture Meets the Military,” Medical Acupuncture 29, no. 4 (2017): 189–90.

31. M. S. Corbett et al., “Acupuncture and other Physical Treatments for the Relief of Pain Due to Osteoarthritis of the Knee: Network Meta-analysis,” Osteoarthritis and Cartilage 21, no. 9 (2013): 1290–98; John McDonald and Stephen Janz, The Acupuncture Evidence Project: A Comprehensive Literature Review, rev. ed. (Brisbane: Australian Acupuncture & Chinese Medicine Association Limited, 2017); Andrew J. Vickers et al., “Acupuncture for Chronic Pain: Individual Patient Data Meta-Analysis,” Archives of Internal Medicine 172, no. 19 (2012): 1444–53; and Marcus Gadau et al., “Acupuncture and Moxibustion for Lateral Elbow Pain: A Systematic Review of Randomized Controlled Trials,” BMC Complementary and Alternative Medicine 14 (2014): 136.

32. “Mandated Benefit Review of H.B. 3972: An Act Relative to the Practice of Acupuncture,” Center for Health Information and Analysis, April 2015, http://www.aomsm.org/Resources/Documents/Research/BenefitReview-H3972-Acupuncture.pdf.

33. F. E. Motlagh, F. Ibrahim, R. A. Rashid, T. Seghatoleslam, and H. Habil, “Acupuncture Therapy for Drug Addiction,”Chinese Medicine 11, no. 16 (2017). doi:10.1186 /s13020-016-0088-7.

34. Jaung-Geng Lin, Yuan-Yu Chan, and Yi-Hung Chen, “Acupuncture for the Treatment of Opiate Addiction,” Evidence-Based Complementary and Alternative Medicine 2012 (2012). doi:10.1155/2012/739045.

35. Liu-Zhen Wu et al., “Suppression of Morphine Withdrawal by Electroacupuncture in Rats: Dynorphin and Kappa-Opioid Receptor Implicated,” Brain Research 851, nos. 1–2 (1999): 290–96.

36. Bei-Hung Chang and Elizabeth Sommers, “Acupuncture and Relaxation Response for Craving and Anxiety Reduction among Military Veterans in Recovery from Substance Use Disorder,” American Journal of Addiction 23, no. 2 (2014): 129–36.

37. National Acupuncture Detoxification Association, “About NADA,” http://www.acudetox.com/about-nada/12faqs2013.

38. Diane Swengros et al., “Promoting Caring-Healing Relationships: Bringing Healing Touch to the Bedside in a Multihospital Health System,” Holistic Nurse Practitioner 28, no. 6 (2014): 370–75; and Joel G. Anderson et al., “The Effects of Healing Touch on Pain, Nausea, and Anxiety Following Bariatric Surgery: A Pilot Study,” Explore 11, no. 3 (2015): 208–16.

39. J. W. Boland, G. A. Foulds, S. H. Ahmedzai, and A. G. Pockley, “A Preliminary Evaluation of the Effects of Opioids on Innate and Adaptive Human In Vitro Immune Function,” BMJ Supportive and Palliative Care 4, no. 4 (2014): 357–67.

40. B. Pajusco et al., “Tobacco Addiction and Smoking Status in Heroin Addicts under Methadonevs.Buprenorphine Therapy,”International Journal of Environmental Research and Public Health9, no. 3 (2012): 932–42. doi:10.3390 /ijerph9030932.

41. U.S. National Institutes of Health, LiverTox, “Drug Record: Opioids, Opioid Antagonists,” https://livertox.nlm.nih.gov/Opioids.htm#overview, accessed March 31, 2018.

42. H. Hedegaard, M. Warner, and A. Minino, “Drug Overdose Deaths in the United States, 1999–2016,” U.S. Centers for Disease Control and Prevention, National Center for Health Statistics, NCHS Data Brief no. 294 (December 2017), https://www.cdc.gov/nchs/products/databriefs/db294.htm.

43. Ian Musgrave, “Study Reveals That Nearly 90% of Traditional Chinese Medicines Contain Trace Amounts of Disturbing and Toxic Substances,” Business Insider, December 13, 2015, http://www.businessinsider.com/study-reveals-chinese-medicines-contain-trace-amounts-of-toxic-substances-2015-12.

44. Morgan A. Pratte et al., “An Alternative Treatment for Anxiety: A Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha (Withania somnifera),” Journal of Alternative and Complementary Medicine 20, no. 12 (December 2014): 901–8.

45. Manuel Candelario et al., “Direct Evidence for GABAergic Activity of Withania somnifera on Mammalian Ionotropic GABAA and GABAρ Receptors,” Journal of Ethnopharmacology 171 (August 2, 2015): 264–72.

46. Dnyanraj Choudhary, Sauvik Bhattacharyya, and Kedar Joshi et al., “Body Weight Management in Adults under Chronic Stress through Treatment with Ashwagandha Root Extract: A Double-Blind, Randomized, Placebo-Controlled Trial,” Journal of Evidence-Based Complementary Inegrative Medicine 22, no. 1 (January 2017): 96–106.

47. Yue Wang et al., “Astragalus saponins Inhibits Lipopolysaccharide-Induced Inflammation in Mouse Macrophages,” American Journal of Chinese Medicine 44, no. 3 (2016): 579–93; Kathy K. Auyeung, Quin-Ban Han, and Joshua K. Ko, “Astragalus membranaceus: A Review of Its Protection against Inflammation and Gastrointestinal Cancers,” American Journal of Chinese Medicine 44, no. 1 (2016): 1–22; and Wei Wei et al., “TLR-4 May Mediate Signaling Pathways of Astragalus Polysaccharide RAP Induced Cytokine Expression of RAW264.7 Cells,” Journal of Ethnopharmacology 179 (2016): 243–52.

48. Chien-Liang Chao et al., “Sesquiterpenes from Baizhu Stimulate Glucose Uptake by Activating AMPK and PI3K,” American Journal of Chinese Medicine 44, no. 5 (2016): 963–79.

49. Fangyi Long et al., “Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells,” Medical Science Monitor 23 (2017): 571–79.

50. Na Zhang et al., “Two New Compounds from Atractylodes macrocephala with Neuroprotective Activity,” Journal of Asian Natural Products Research 19, no. 1 (January 2017): 35–41; and Xin Fu et al., “New Hope for Alzheimer’s Disease,” Aging and Disease 7, no. 4 (August 2016): 502–13.

51. Le Son Hoang et al., “Inflammatory Inhibitory Activity of Sesquiterpenoids from Atractylodes macrocephala Rhizomes,” Chemical and Pharmceutical Bulletin 64, no. 5 (2016): 507–11.

52. Suresh Awale et al., “Identification of Arctigenin as an Antitumor Agent Having the Ability to Eliminate the Tolerance of Cancer Cells to Nutrient Starvation,” Cancer Research 66, no. 3 (2006): 1751–57; and Siti Susanti et al., “Tumor Specific Cytotoxicity of Arctigenin Isolated from Herbal Plant Arctium lappa L.,” Journal of Natural Medicines 66, no. 4 (2012): 614–21.

53. Song-Chow Lin et al., “Hepatoprotective Effects of Arctium lappa Linne on Liver Injuries Induced by Chronic Ethanol Consumption and Potentiated by Carbon Tetrachloride,” Journal of Biomedical Science 9, no. 5 (2002): 401–9.

54. Akram Ahangarpour et al., “Antidiabetic, Hypolipidemic and Hepatoprotective Effects of Arctium lappa Root’s Hydro-alcoholic Extract on Nicotinamide-Streptozotocin Induced Type 2 Model of Diabetes in Male Mice,” Avicenna Journal of Phytomedicine 7, no. 2 (2017): 169–79.

55. National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (Washington, DC: The National Academies Press, 2017).

56. Philippe Lucas, “Rationale for Cannabis-Based Interventions in the Opioid Overdose Crisis,” Harm Reduction Journal 14, no. 58 (2017).

57. Kevin F. Boehnke, Evangelos Litinas, and Daniel J. Clauw, “Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain,” Journal of Pain 17, no. 6 (2016): 739–44.

58. National Academies of Sciences, Health Effects of Cannabis.

59. Yong-Xu Sun, “Immunological Adjuvant Effect of a Water-Soluble Polysaccharide, CPP, from the Roots of Codonopsis pilosula on the Immune Responses to Ovalbumin in Mice,” Chemistry & Biodiversity 6, no. 6 (June 2009): 890–96.

60. Chong Xu et al., “The Contribution of Side Chains to Antitumor Activity of a Polysaccharide from Codonopsis pilosula,” International Journal of Biological Macromolecules 50, no. 4 (May 1, 2012): 891–94; and Xu Chu et al., “Effects of Astragalus and Codonopsis pilosula Polysaccharides on Alveolar Macrophage Phagocytosis and Inflammation in Chronic Obstructive Pulmonary Disease Mice Exposed to PM2.5,” Environmental Toxicology and Pharmacology 48 (December 2016): 76–84.

61. Dirleise Colle et al., “Antioxidant Properties of Taraxacum officinale Leaf Extract Are Involved in the Protective Effect against Hepatoxicity Induced by Acetaminophen in Mice,” Journal of Medicinal Food 15, no. 6 (2012): 549–56; and Muhammad Gulfraz et al., “Effect of Leaf Extracts of Taraxacum officinale on CCl4 Induced Hepatotoxicity in Rats, In Vivo Study,” Pakistan Journal of Pharmaceutical Science 27, no. 4 (2014): 825–29.

62. Munkhtugs Davaatseren et al., “Taraxacum official (Dandelion) Leaf Extract Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver,” Food and Chemical Toxicology 58 (August 2013): 30–36.

63. Jing Wang et al., “Isoalantolactone Inhibits the Migration and Invasion of Human Breast Cancer MDA-MB-231 Cells via Suppression of the p38 MAPK/NF-κB Signaling Pathway,” Oncololgy Reports 36, no. 3 (2016): 1269–76.

64. Shuang Gao et al., “Total Sesquiterpene Lactones Prepared from Inula helenium L. Has Potentials in Prevention and Therapy of Rheumatoid Arthritis,” Journal of Ethnopharmacolology 196 (2017): 39–46.

65. Lin-Zhang Huang et al., “Antifatigue Activity of the Liposoluble Fraction from Acanthopanax senticosus,” Phytotherapy Research 25, no. 6 (June 2011): 940–43.

66. Alexander Panossian et al., “Adaptogens Stimulate Neuropeptide Y and Hsp72 Expression and Release in Neuroglia Cells,” Frontiers in Neuroscience 6, no. 6 (February 1, 2012).

67. Ji-Nian Fang, A. Proksch, and Hildebert Wagner, “Immunologically Active Polysaccharides of Acanthopanax senticosus,” Phytochemistry 24, no. 11 (1985): 2619–22.

68. Sun Young Park et al., “Anti-inflammatory Effects of Novel Polygonum Multiflorum Compound via Inhibiting NF-κB/MAPK and Upregulating the Nrf2 Pathways in LPS-Stimulated Microglia,” Neuroscience Letters 651 (June 9, 2017): 43–51; and Rui Li et al., “Antiaging and Anxiolytic Effects of Combinatory Formulas Based on Four Medicinal Herbs,” Evidence-Based Complementary and Alternative Medicine 2017 (2017): Article ID 4624069.

69. Chunyu Li et al., “Screening for Main Components Associated with the Idiosyncratic Hepatotoxicity of a Tonic Herb, Polygonum multiflorum,” Frontiers of Medicine 11, no. 2 (2017): 253–65.

70. Ya-Min Hou, Jie Wang, and Xian-Zhao Zhang, “Lycium Barbarum Polysaccharide Exhibits Cardioprotection in an Experimental Model of Ischemia-Reperfusion Damage,” Molecular Medicine Report 15, no. 5 (2017): 2653–58; and You Jin Lee et al., “Dietary Wolfberry Extract Modifies Oxidative Stress by Controlling the Expression of Inflammatory mRNAs in Overweight and Hypercholesterolemic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial,” Journal of Agricultural Food Chemistry 65, no. 2 (2017): 309–16.

71. Mi Hye Kim et al., “Improvement of Osteoporosis by Lycium Chinense Administration in Ovariectomized Mice,” Journal of the Chinese Medical Association 80, no. 4 (2017): 222–26.

72. Ilkay Erdogan Orhan, “Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) — A Cardiotonic Herb,” Current Medical Chemistry 23 (2016); Simone Fuchs et al., “The Dual Edema-Preventing Molecular Mechanism of the Crataegus Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions,” Planta Medica 83, no. 8 (2017): 701–9; Gary N. Asher et al., “Effect of Hawthorn Standardized Extract on Flow Mediated Dilation in Prehypertensive and Mildly Hypertensive Adults: A Randomized, Controlled Cross-over Trial,” BMC Complementary and Alternative Medicine 12, no. 26 (2012); and Abdoulaye Diane et al., “Hypolipidemic and Cardioprotective Benefits of a Novel Fireberry Hawthorn Fruit Extract in the JCR:LA-cp Rodent Model of Dyslipidemia and Cardiac Dysfunction,” Food & Function 7, no. 9 (2016): 3943–52.

73. Yantao Li et al., “Anti-cancer Effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan),” Chinese Medicine 11, no. 43 (2016).

74. Ezarul Lokman et al., “Evaluation of Antidiabetic Effects of the Traditional Medicinal Plant Gynostemma pentaphyllum and the Possible Mechanisms of Insulin Release,” Evidence-Based Complementary Alternative Medicine 2015 (2015): Article ID 120572.

75. Qin He et al., “Mechanism of Action of Gypenosides on Type 2 Diabetes and Non-alcoholic Fatty Liver Disease in Rats,” World Journal of Gastroenterology 21, no. 7 (2015): 2058–66.

76. Eduardo Cinosi et al., “Following ‘the Roots’ of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries,”BioMed Research International (2015): Article ID 968786.

77. Batool Rahmati et al., “Antidepressant and Anxiolytic Activity of Lavandula officinalis Aerial Parts Hydroalcoholic Extract in Scopolamine-Treated Rats,” Pharmceutical Biology 55, no. 1 (2017): 958–65.

78. Ji Hyun Baek, Andrew A. Nierenberg, and Gustavo Kinrys, “Clinical Applications of Herbal Medicines for Anxiety and Insomnia; Targeting Patients with Bipolar Disorder,” Australian & New Zealand Journal of Psychiatry 48, no. 8 (2014): 705–15; and Abolfazl Shakeri, Amirhossein Sahebkar, and Behjat Javadi, “Melissa officinalis L. — A Review of Its Traditional Uses, Phytochemistry and Pharmacology,” Journal of Ethnopharmacology 188 (2016): 204–28.

79. Daniil N. Olennikov, Nina I. Kashchenko, and Nadezhda K. Chirikova, “Meadowsweet Teas as New Functional Beverages: Comparative Analysis of Nutrients, Phytochemicals and Biological Effects of Four Filipendula Species,” Molecules 22, no. 1 (2017): 16; Jelena Katanić et al., “In Vitro and In Vivo Assessment of Meadowsweet (Filipendula ulmaria) as Anti-inflammatory Agent,” Journal of Ethnopharmacology 193 (2016): 627–36; Anca Toiu et al., “HPLC Analysis of Salicylic Derivatives from Natural Products,” Farmacia 59, no. 1 (2011): 106–12; and Jeanette Wick, “Aspirin: A History, a Love Story,” Consultant Pharmacist 27, no. 5 (2012): 322–29.

80. Simon Mills and Kerry Bone, Principles and Practice of Phytotherapy: Modern Herbal Medicine (Edinburgh: Churchill Livingstone, 2000), 60–61, 148–49, 479–82.

81. Katarzyna Wojtyniak, Marcin Szymański, and Irena Matławska, “Leonurus cardiaca L. (Motherwort): A Review of Its Phytochemistry and Pharmacology,” Phytotherapy Research 27, no. 8 (2013): 1115–20.

82. Alexander N. Shikov et al., “Effect of Leonurus cardiaca Oil Extract in Patients with Arterial Hypertension Accompanied by Anxiety and Sleep Disorders,” Phytotherapy Research 25, no. 4 (2011): 540–43.

83. Kurt Appel et al., “Modulation of the γ-Aminobutyric Acid (GABA) System by Passiflora incarnata L.,” Phytotherapy Research 25, no. 6 (June 2011): 838–43.

84. James Ahn et al., “Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy,”Neural Plasticity(2016): Article ID 1320423.

85. Urooj Aman et al., “Passiflora incarnataAttenuation of Neuropathic Allodynia and Vulvodynia Apropos GABA-ergic and Opioidergic Antinociceptive and Behavioural Mechanisms,”BMC Complementary and Alternative Medicine16, no. 77 (2016).

86. Chun Hay Ko et al., “Multitargeted Combination Effects of a Tri-herbal Formulation Containing ELP against Osteoporosis: In Vitro Evidence,” Journal of Pharmacy and Pharmacology 68, no. 6 (2016): 826–33.

87. Xiao-peng Hu et al., “Anti-influenza Virus Effects of Crude Phenylethanoid Glycosides Isolated from Ligustrum purpurascens via Inducing Endogenous Interferon-γ,” Journal of Ethnopharmacology 179 (2016): 128–36; V. Katalinic et al., “Screening of 70 Medicinal Plant Extracts for Antioxidant Capacity and Total Phenols,” Food Chemistry 94 (2006): 550–57; and Hye Lim Seo et al., “Liqustri lucidi Fructus Inhibits Hepatic Injury and Functions as an Antioxidant by Activation of AMP-Activated Protein Kinase In Vivo and In Vitro,” Chemico-Biological Interactions 262 (2017): 57–68.

88. Cheng-Chieh Chang et al., “Oxidative Stress and Salvia miltiorrhiza in Aging-Associated Cardiovascular Diseases,” Oxidative Medicine and Cellular Longevity 2016 (2016): Article ID 4797102.

89. Laura Bonaccini et al., “Effects of Salvia miltiorrhiza on CNS Neuronal Injury and Degeneration: A Plausible Complementary Role of Tanshinones and Depsides,” Planta Medica 81, nos. 12–13 (2015): 1003–16; and Chun-Yan Su et al., “Salvia miltiorrhiza: Traditional Medicinal Uses, Chemistry, and Pharmacology,” Chinese Journal of Natural Medicines 13, no. 3 (2015): 163–82.

90. Yuan Yuan et al., “Advance in Studies on Hepatoprotective Effect of Salvia miltiorrhiza and Its Main Components,” Zhongguo Zhong Yao Za Zhi 40, no. 4 (2015): 588–93.

91. Antonnio Barbieri et al., “Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment,” Nutrients 9, no. 3 (2017): 210; Balraj Singh Gill, Sanjeev Kumar, and Navgeet, “Ganoderic Acid Targeting Nuclear Factor Erythroid 2-Related Factor 2 in Lung Cancer,” Tumor Biology 39, no. 3 (2017): 1–12; and Kun Na et al., “Anticarcinogenic Effects of Water Extract of Sporoderm-Broken Spores of Ganoderma lucidum on Colorectal Cancer In Vitro and In Vivo,” Internal Journal of Oncology 50, no. 5 (2017): 1541–54.

92. Deng Pan et al., “Antidiabetic, Antihyperlipidemic and Antioxidant Activities of a Novel Proteoglycan from Ganoderma lucidum Fruiting Bodies on db/db Mice and the Possible Mechanism,” PLoS One 8, no. 7 (2013): e68332.

93. Fangjiao Song et al., “Schizandrin A Inhibits Microglia-Mediated Neuroninflammation through Inhibiting TRAF6-NF-κB and Jak2-Stat3 Signaling Pathways,” PLoS One 11, no. 2 (2016): e0149991.

94. Tingxu Yan et al., “Lignans from Schisandra chinensis Ameliorate Cognition Deficits and Attenuate Brain Oxidative Damage Induced by D-galactose in Rats,” Metabolic Brain Disease 31, no. 3 (2016): 653–61.

95. K. M. Ko et al., “Effect of a Lignan-Enriched Fructus Schisandrae Extract on Hepatic Glutathione Status in Rats: Protection against Carbon Tetrachloride Toxicity,” Planta Medica 61, no. 2 (1995): 134–37.

96. Shobhit Srivastava et al., “Curcuma longa Extract Reduces Inflammatory and Oxidative Stress Biomarkers in Osteoarthritis of Knee: A Four-Month, Double-Blind, Randomized, Placebo-Controlled Trial,” Inflammopharmacology 24, no. 6 (2016): 377–88; K. Madhu, Chanda Kulkarni, and M. J. Saji, “Safety and Efficacy of Curcuma longa Extract in the Treatment of Painful Knee Osteoarthritis: A Randomized Placebo-Controlled Trial,” Inflammopharmacology 21, no. 2 (2013): 129–36; and Ashok Kumar Grover and Sue E. Samson, “Benefits of Antioxidant Supplements for Knee Osteoarthritis: Rationale and Reality,” Nutrition Journal 15, no. 1 (2016).

97. H. Hatcher, et al., “Curcumin: From Ancient Medicine to Current Clinical Trials,” Cellular and Molecular Life Sciences, 65, no. 11 (2008): 1631–52.

98. Feng-Mei Qiu et al., “The Antidepressant-Like Effects of Paeoniflorin in Mouse Models,”Experimental and Therapeutic Medicine5, no. 4 (2013): 1113–16; and Feng-Mei Qiu et al., “Antidepressant-like Effects of Paeoniflorin on the Behavioral, Biochemical, and Neurochemical Patterns of Rats Exposed to Chronic Unpredictable Stress,”Neuroscience Letters 541 (2013): 209–13.

99. Zhenyu Zhou et al., “Paeoniflorin Prevents Hypoxia-Induced Epithelial-Mesenchymal Transition in Human Breast Cancer Cells,”Oncology Targets and Therapy 2016, no. 9 (2016): 2511–18.

100. A. Wesołowska et al., “Analgesic and Sedative Activities of Lactucin and Some Lactucin-Like Guaianolides in Mice,” Journal of Ethnopharmacology 107, no. 2 (2006): 254–58.

101. Ibid.

102. Sima Besharat, Mahsa Besharat, and Ali Jabbari, “Wild Lettuce (Lactuca virosa) Toxicity,” BMJ Case Reports (2009). doi:10.1136/bcr.06.2008.0134.

103. Ensiyeh Jenabi and Bita Fereidoony, “Effect of Achillea millefolium on Relief of Primary Dysmenorrhea: A Double-Blind Randomized Clinical Trial,” Journal of Pediatric & Adolescent Gynecology 28, no. 5 (2015): 402–4; and Maryam Hajhashemi et al., “The Effect of Achillea millefolium and Hypericum perforatum Ointments on Episiotomy Wound Healing in Primiparous Women,” Journal of Maternal-Fetal & Neonatal Medicine 31, no. 1 (2018): 63–69.

104. Zoran Maksimović et al., “Antioxidant Activity of Yellow Dock (Rumex crispus L., Polygonaceae) Fruit Extract,” Phytotherapy Research 25, no. 1 (2011): 101–5; and Supriya Shiwani, Naresh Kumar Singh, and Myeong Hyeon Wang, “Carbohydrase Inhibition and Anti-cancerous and Free Radical Scavenging Properties along with DNA and Protein Protection Ability of Methanolic Root Extracts of Rumex crispus,” Nutrition Research and Practice 6, no. 5 (2012): 389–95.

105. Xuesheng Han and Tory L. Parker, “Antiinflammatory Activity of Cinnamon (Cinnamomum zeylanicum) Bark Essential Oil in a Human Skin Disease Model,” Phytotherapy Research 31, no. 7 (2017): 1034–38.

106. Xuesheng Han and Tory L. Parker, “Anti-inflammatory Activity of Clove (Eugenia caryophyllata) Essential Oil in Human Dermal Fibroblasts,” Pharmaceutical Biology 55, no. 1 (2017): 1619–22.

107. M. A. Davis, L. A. Lin, H. Liu, and B. D. Sites, “Prescription Opioid Use among Adults with Mental Health Disorders in the United States,” Journal of the American Board of Family Medicine 30, no. 4 (2017): 407–17.

108. E. Bach, The Twelve Healers and Other Remedies (Pilgrims Publishing, 2002), 25.

109. Ibid.

110. Sepideh Nabipour, Mas Ayu Said, and Mohd Hussain Habil, “Burden and Nutritional Deficiencies in Opioid Addiction — Systematic Review Article,” Iran Journal of Public Health 43, no. 8 (2014): 1022–32.

111. Ibid.

112. Lawrence Feinman, “Absorption and Utilization of Nutrients in Alcoholism,” Alcohol Health & Research World 13, no. 3 (1989): 207–10.

113. John Finnegan and Daphne Gray, Recovery from Addiction: A Comprehensive Understanding of Substance Abuse with Nutritional Therapies for Recovering Addicts and Co-dependents (Berkeley, CA: Celestial Arts, 1990); Mihai Nechifor, “Magnesium in Drug Dependences,” Magnesium Research 21, no. 1 (2008): 5–15; and George A. Eby and Karen L. Eby, “Rapid Recovery from Major Depression Using Magnesium Treatment,” Medical Hypotheses 67, no. 2 (2006): 362–70.

114. Malcolm Peet and Caroline Stokes, “Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders,” Drugs 65, no. 8 (2005): 1051–59.

115. Wojciech Leppert, “The Impact of Opioid Analgesics on the Gastrointestinal Tract Function and the Current Management Possibilities,” Contemporary Oncology 16, no. 2 (2012): 125–31; and Tiziana Larussa, Maria Imeneo, and Francesco Luzza, “Potential Role of Nutraceutical Compounds in Inflammatory Bowel Disease,” World Journal of Gastroenterology 14, no. 23 (2017): 2483–92.

116. John E. Lewis et al., “The Effect of Methylated Vitamin B Complex on Depressive and Anxiety Symptoms and Quality of Life in Adults with Depression,” International Scholarly Research Notes: Psychiatry (2013): Article ID 621453.

117. Angela Sorice et al., “Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases,” Mini Reviews in Medicinal Chemisry 14, no. 5 (2014): 444–52.

118. A. Evangelou et al., “Ascorbic Acid (Vitamin C) Effects on Withdrawal Syndrome of Heroin Abusers,” In Vivo 14, no. 2 (2000): 363–66.

119. Kathleen DesMaisons, Potatoes Not Prozac: A Natural Seven-Step Dietary Plan to Control Your Cravings and Lose Weight(Old Tappan, NJ: Fireside 1999),79.

120. Lukas Pezawas et al., “5-HTTLPR Polymorphism Impacts Human Cingulate-Amygdala Interactions: A Genetic Susceptibility Mechanism for Depression,” Nature Neuroscience 8, no. 6 (2005): 828–34.

121. J. A. Schinka, R. M. Busch, and N. Robichaux-Keene, “A Meta-analysis of the Association between the Serotonin Transporter Gene Polymorphism (5-HTTLPR) and Trait Anxiety,” Molecular Psychiatry 9, no. 2 (2004): 197–202.

122. Jessica M. Yano et al., “Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis,”Cell161, no. 2 (2015): 264–76.

123. Andrzej Slominski et al., “Conversion of L-Tryptophan to Serotonin and Melatonin in Human Melanoma Cells,” FEBS Letters 511, nos. 1–3 (2002): 102–6.

124. Adham M. Abdou et al., “Relaxation and Immunity Enhancement Effects of γ-Aminobutyric Acid (GABA) Administration in Humans,” Biofactors 26, no. 3 (2006): 201–8.

125. Laura Steenbergen et al., “Transcutaneous Vagus Nerve Stimulation (tVNS) Enhances Response Selection during Action Cascading Processes,” European Neuropsychopharmacology 25, no. 6 (2015): 773–78.

126. Tsutomu Kanehira et al., “Relieving Occupational Fatigue by Consumption of a Beverage Containing γ-Amino Butyric Acid,” Journal of Nutritional Science and Vitaminology 57, no. 1 (2011): 9–15.

127. Masahito Watanabe et al., “GABA and GABA Receptors in the Central Nervous System and Other Organs,” International Review of Cytology 213 (2002): 1–47.

128. D. D. Rasmussen et al., “Effects of Tyrosine and Tryptophan Ingestion on Plasma Catecholamine and 3,4-Dihydroxyphenylacetic Acid Concentrations,” Journal of Clinical Endocrinology and Metabolism 57, no. 4 (1983): 760–63.

129. Wolfram Schultz, “Neuronal Reward and Decision Signals: From Theories to Data,”Physiological Reviews95, no. 3 (2015): 853–951.

130. Eric J. Nestler, “Transcriptional Mechanisms of Drug Addiction,” Clinical Psychopharmacology and Neuroscience 10, no. 3 (2012): 136–43.

131. Rajita Sinha, “The Clinical Neurobiology of Drug Craving,” Current Opinion in Neurobiology 23, no. 4 (2013): 649–54; and B. T. Thomas Yeo et al., “The Organization of the Human Cerebral Cortex Estimated by Intrinsic Functional Connectivity,” Journal of Neurophysiology 106, no. 3 (2011): 1125–65.

132. Harris R. Lieberman et al., “The Effects of Dietary Neurotransmitter Precursors on Human Behavior,” American Journal of Clinical Nutrition 42, no. 2 (1985): 366–70; Richard A. Magill et al., “Effects of Tyrosine, Phentermine, Caffeine D-Amphetamine, and Placebo on Cognitive and Motor Performance Deficits during Sleep Deprivation,” Nutritional Neuroscience 6, no. 4 (2003): 237–46; and David F. Neri et al., “The Effects of Tyrosine on Cognitive Performance during Extended Wakefulness,” Aviation, Space, and Environmental Medicine 66, no. 4 (1995): 313–19.

133. “IUPHAR/BPS Guide to PHARMACOLOGY,” International Union of Basic and Clinical Pharmacology, March 15, 2017, http://www.guidetoimmunopharmacology.org/immuno/index.jsp; and Yingxue Li et al., “Opioid Glycopeptide Analgesics Derived from Endogenous Enkephalins and Endorphins,”Future Medicinal Chemistry4, no. 2 (2012): 205–26.

134. R. R. W. J. van der Hulst et al., “Glutamine and the Preservation of Gut Integrity,” Lancet 341, no. 8857 (1993): 1363–65; Fatma G. Huffman and Melanie E. Walgren, “L-Glutamine Supplementation Improves Nelfinavir-Associated Diarrhea in HIV-Infected Individuals,” HIV Clinical Trials 4, no. 5 (2003): 324–29.

135. Jan Albrecht et al., “Roles of Glutamine in Neurotransmission,” Neuron Glia Biology 6, no. 4 (2010): 263–76.

136. Itzhak Nissim et al., “Acid-Base Regulation of Hepatic Glutamine Metabolism and Ureagenesis: Study with 15N,” Journal of the American Society of Nephrology 3, no. 7 (1993): 1416–27.

137. Zayd Merza, “Chronic Use of Opioids and the Endocrine System,” Hormone and Metabolic Research 42, no. 9 (2010): 621–26; and J. A. Elliott, S. E. Opper, S. Agarwal, and E. E. Fibuch, “Non-analgesic Effects of Opioids: Opioids and the Endocrine System,” Current Pharmacology Discussion 18, no. 37 (2012): 6070–78.

138. Alessandro Colasanti et al., “Opioids and Anxiety,” Journal of Psychopharmacology 25, no. 11 (2011): 1415–33.

139. Robert M. Swift and Robert L. Stout, “The Relationship between Craving, Anxiety, and Other Symptoms in Opioid Withdrawal,” Journal of Substance Abuse 4, no. 1 (1992): 19–26.

140. Rikita Merai et al., “CDC Grand Rounds: A Public Health Approach to Detect and Control Hypertension,”Morbidity and Mortality Weekly Report 65, no. 45 (2016): 1261–64.

141. Dariush Mozzafarian et al., “Heart Disease and Stroke Statistics — 2015 Update: A Report from the American Heart Association,”Circulation 131, no. 4 (January 27, 2015): e29–e322.

142. Howard S. Smith, “Opioid Metabolism,”Mayo Clinic Proceedings84, no. 7 (2009): 613–24.

143. Maria C. Mancebo et al., “Substance Use Disorders in an Obsessive Compulsive Disorder Clinical Sample,” Journal of Anxiety Disorders 23, no. 4 (2009): 429–35; and Irit Friedman, Reuven Dar, and Etay Shilony, “Compulsivity and Obsessionality in Opioid Addiction,” Journal of Nervous and Mental Disease 188, no. 3 (March 2000): 155–62.

144. Jane Liebschutz et al., “The Relationship between Sexual and Physical Abuse and Substance Abuse Consequences,”Journal of Substance Abuse Treatment22, no. 3 (2002): 121–28.

145. Courtney Lee et al., “The Effectiveness of Acupuncture Research across Components of the Trauma Spectrum Response (TSR): A Systematic Review of Reviews,”Systematic Reviews1, no. 46 (2012); Wayne B. Jonas et al., “A Randomized Exploratory Study to Evaluate Two Acupuncture Methods for the Treatment of Headaches Associated with Traumatic Brain Injury,”Medical Acupuncture28, no. 3 (2016): 113–30; and Charles C. Engel et al., “Randomized Effectiveness Trial of a Brief Course of Acupuncture for Posttraumatic Stress Disorder,” Medical Care 52 (2014): S57–S64.

146. Mark A. Micek et al., “Complementary and Alternative Medicine Use among Veterans Affairs Outpatients,” Journal of Alternative and Complementary Medicine 13, no. 2 (2007): 190–93.

147. F. Patricia McEachrane-Gross, Jane Liebschutz, and Dan Berlowitz, “Use of Selected Complementary and Alternative Medicine (CAM) Treatments in Veterans with Cancer or Chronic Pain: A Cross-Sectional Survey,”BMC Complementary and Alternative Medicine 6, no. 34 (2006).

148. Barbara Goldberg, “Opioid Abuse Crisis Takes Heavy Toll on U.S. Veterans,” Reuters, November 10, 2017, https://www.reuters.com/article/us-usa-veterans-opioids/opioid-abuse-crisis-takes-heavy-toll-on-u-s-veterans-idUSKBN1DA1B2; and Sarah Childress, “Veterans Face Greater Risks Amid Opioid Crisis,” PBS Frontline, March 28, 2016, https://www.pbs.org/wgbh/frontline/article/veterans-face-greater-risks-amid-opioid-crisis/.

149. Thomas F. Northrup et al., “Opioid Withdrawal, Craving, and Use During and After Outpatient Buprenorphine Stabilization and Taper: A Discrete Survival and Growth Mixture Model,” Addictive Behaviors 41 (February 2105): 20–28.

150. Sompon Wanwimolruk and Virapong Prachayasittikul, “Cytochrome P450 Enzyme Mediated Herbal Drug Interactions (Part 1),” Experimental and Clinical Sciences Journal 13 (2014): 347–91.

151. Lin Kang et al., “Tai-Kang-Ning, a Chinese Herbal Medicine Formula, Alleviates Acute Heroin Withdrawal,” American Journal of Drug and Alcohol Abuse 34, no. 3 (2008): 269–76.

152. M. J. Christie, “Cellular Neuroadaptations to Chronic Opioids: Tolerance, Withdrawal and Addiction,” British Journal of Pharmacology 154 (2008): 384–96; and Ashish K. Rehni, Amteshwar S. Jaggi, and Nirmal Singh, “Opioid Withdrawal Syndrome: Emerging Concepts and Novel Therapeutic Targets,” CNS & Neurological Disorders: Drug Targets 12, no. 1 (2013): 112–25.

153. Christopher M. Jones, “Heroin Use and Heroin Use Risk Behaviors among Nonmedical Users of Prescription Opioid Pain Relievers: United States, 2002–2004 and 2008–2010,” Drug and Alcohol Dependence 132, nos. 1–2 (2013): 95–100.

154. Elizabeth Llorente, “New Jersey’s New Opioid Law Raises Concerns among Doctors,” Fox News Health, May 9, 2017, http://www.foxnews.com/health/2017/05/09/new-jerseys-new-opioid-law-raises-concerns-among-doctors.html; and Eric Russell, “Legislators Urged to Clarify Opioid Law That Restricts Long-Term Use of Painkillers,” Portland Press Herald, April 20, 2017, http://www.pressherald.com/2017/04/20/chronic-pain-patients-say-new-law-regulating-opioid-prescriptions-is-harming-them/.

155. Richard L. Nahin et al., “Evidence-Based Evaluation of Complementary Health Approaches for Pain Management in the United States,” Mayo Clinic Proceedings 91, no. 9 (2016): 1292–306; María Villarreal Santiago et al., “Does Acupuncture Alter Pain-Related Functional Connectivity of the Central Nervous System? A Systematic Review,” Journal of Acupuncture and Meridian Studies 9, no. 4 (2016): 167–77; and Alena Ondrejkovicova et al., “Why Acupuncture in Pain Treatment?,” Neuroendocrinology Letters 37, no. 3 (2016): 163–68.

156. Li-Xin An et al., “Electro-Acupuncture Decreases Postoperative Pain and Improves Recovery in Patients Undergoing Supratentorial Craniotomy,” American Journal of Chinese Medicine 42, no. 5 (2014): 1099–109; Chun-Chieh Chen et al., “Acupuncture for Pain Relief after Total Knee Arthroplasty: A Randomized Controlled Trial,” Regional Anesthesia and Pain Medicine 40, no. 1 (2015): 31–36; Hye Kyung Cho et al., “Can Perioperative Acupuncture Reduce the Pain and Vomiting Experienced after Tonsillectomy? A Meta-Analysis,” Laryngoscope 126, no. 3 (2016): 608–15; Young-Hun Cho et al., “Acupuncture for Acute Postoperative Pain after Back Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” Pain Practice 15, no. 3 (2015): 279–91; and Daniel J. Crespin et al., “Acupuncture Provides Short-Term Pain Relief for Patients in a Total Joint Replacement Program,” Pain Medicine 16, no. 6 (2015): 1195–203.

157. Leslie J. Crofford, “Chronic Pain: Where the Body Meets the Brain,” Transactions of the American Clinical and Climatological Association126 (2015): 167–83.

158. Chris Bleakley, Suzanne McDonough, and Domhnall MacAuley, “The Use of Ice in the Treatment of Acute Soft-Tissue Injury,” American Journal of Sports Medicine 32, no. 1 (2004): 251–61.

159. D. Dent-Breen, “Rethinking RICE: The Old Standard Method May Not Actually Be the Best Treatment for Acute Injuries,” EmaxHealth, July 12, 2017, https://www.emaxhealth.com/13737/rethinking-rice-old-standard-method-may-not-actually-be-best-treatment-acute-injuries.

160. P. Rapeli et al., “Cognitive Function during Early Abstinence from Opioid Dependence: A Comparison to Age, Gender, and Verbal Intelligence Matched Controls,” BMC Psychiatry 6 (2006): 9.

161. “Many Fentanyl and Heroin Overdose Survivors Suffering Permanent Brain Damage,” The Dunes East Hampton, March 3, 2017, https://theduneseasthampton.com/blog/many-fentanyl-and-heroin-overdose-survivors-suffering-permanent-brain-damage/.

162. Z. Merza, “Chronic Use of Opioids and the Endocrine System”; J. A. Elliott, S. E. Opper, S. Agarwal, and E. E. Fibuch, “Non-analgesic Effects of Opioids: Opioids and the Endocrine System” Current Pharmacology Discussion 18, no. 37 (2012): 6070–78; and Todd T. Brown, Amy B. Wisniewski, and Adrian S. Dobs, “Gonadal and Adrenal Abnormalities in Drug Users: Cause or Consequence of Drug Use Behavior and Poor Health Outcomes,”American Journal of Infectious Diseases 2, no. 3 (2006): 130–35.

163. Andrew Ellis,Fundamentals of Chinese Acupuncture, rev. ed. (Brookline, MA: Paradigm, 1991).

164. Wojciech Leppert, “The Impact of Opioid Analgesics on the Gastrointestinal Tract Function and the Current Management Possibilities,” Contemporary Oncology 16, no. 2 (2012): 125–31; and Peter Holzer, “Treatment of Opioid-Induced Gut Dysfunction,” Expert Opinion on Investigative Drugs 16, no. 2 (2007): 181–94.

165. Ramsin Benyamin et al., “Opioid Complications and Side Effects,” Pain Physician 11, no. 2S (2008): S105–S120.

166. Samira Alinejad et al., “A Systematic Review of the Cardiotoxicity of Methadone,” EXCLI Journal 14 (May 5, 2015): 577–600; and Erich F. Wedam and Mark C. Haigney, “The Impact of Opioids on Cardiac Electrophysiology,” Current Cardiology Review 12, no. 1 (2016): 27–36.

167. Mirsada Serdarevic et al., “The Association between Insomnia and Prescription Opioid Use: Results from a Community Sample in Northeast Florida,” Sleep Health 3, no. 5 (2017): 368–72; and J. A. Robertson et al., “Sleep Disturbance in Patients Taking Opioid Medication for Chronic Back Pain,”Anaesthesia71, no. 11 (2016): 1296–307.

168. Hooman Khademi et al., “Opioid Therapy and Its Side Effects: A Review,” Archives of Iranian Medicine 19, no. 12 (2016): 873.

169. Rajita Sinha, “Chronic Stress, Drug Use, and Vulnerability to Addiction,” Annals of the New York Academy of Sciences 1141 (October 2008): 105.